The 1D3 monoclonal antibody reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. CD19 contains two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signaling in conjunction with CD21 and CD81. CD19 is highly expressed in most lymphomas and leukemias including some early B-cell malignancies that do not express CD20. For these reasons CD19 is quickly becoming an attractive alternative target for the immunotherapy of lymphoproliferative disorders. The 1D3 antibody has been reported to deplete B cells however, B cell depletion often requires treatment with a combination of 1D3, anti-mouse B220 (clone RA3.3A1/6.1), anti-mouse CD22 (clone Cy34.1), and anti-rat κ light chain (clone MAR 18.5) antibodies. Please see the provided references for protocol details.

產(chǎn)品名稱:InVivoMab anti-mouse CD19

反應(yīng)種屬:mouse

宿主來源:rat

實驗應(yīng)用:in vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, Flow cytometry

同種型:IgG2a, κ

免疫原:K562 cells expressing the extracellular domain of mouse CD19

克隆性:Monoclonal

克隆號:1D3

產(chǎn)品濃度:Lot specific,typically between 4-11 mg/ml

保存溫度:Undiluted at 4°C in the dark

運輸溫度:Ship with adequate amount of blue ice to ensure the product remains at 4°C for the duration of transit

預(yù)期分子量:150 kDa

產(chǎn)品形式:液體

有效期:One year from the date of receipt if stored as recommended

產(chǎn)地:美國

如需購買或咨詢Bioxcell公司的產(chǎn)品，請聯(lián)系Bioxcell*代理商欣博盛生物